Antipolymer Antibody in Italian Fibromyalgia Patients
Author Information
Author(s): Bazzichi Laura, Giacomelli Camillo, De Feo Francesca, Giuliano Tiziana, Rossi Alessandra, Doveri Marica, Tani Chiara, Wilson Russell B, Bombardieri Stefano
Primary Institution: University of Pisa, Pisa, Italy
Hypothesis
Does the presence of antipolymer antibodies correlate with disease severity and cytokine levels in fibromyalgia patients?
Conclusion
Antipolymer antibodies cannot be considered a marker of disease in Italian fibromyalgia patients, but their presence may help identify patients with more severe symptoms.
Supporting Evidence
- 21.05% of fibromyalgia patients tested positive for antipolymer antibodies.
- Patients with moderate and severe symptoms had slightly higher levels of antipolymer antibodies.
- Significant correlations were found between antipolymer antibody levels and the Fibromyalgia Impact Questionnaire scores.
Takeaway
This study looked at a blood test for a specific antibody in fibromyalgia patients to see if it relates to how bad their symptoms are. It turns out the antibody isn't a good marker for the disease, but it might help find patients who are more affected.
Methodology
The study measured antipolymer antibody levels in serum samples using an ELISA kit and assessed cytokine levels and disease severity through questionnaires and scales.
Potential Biases
Potential bias may arise from the exclusion of certain patient groups, which could affect the results.
Limitations
The study excluded patients with silicone breast implants, which may limit the generalizability of the findings.
Participant Demographics
The study included 285 patients, predominantly female (270 females, 15 males), with a median age of 54 years.
Statistical Information
P-Value
P = 0.042 for correlation with Fibromyalgia Impact Questionnaire
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website